[{"address1": "3020 Carrington Mill Blvd.", "address2": "Suite 475", "city": "Morrisville", "state": "NC", "zip": "27560", "country": "United States", "phone": "212 554 4484", "fax": "212 554 4531", "website": "https://www.tgtherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. The company was incorporated in 1993 and is based in Morrisville, North Carolina.", "fullTimeEmployees": 338, "companyOfficers": [{"maxAge": 1, "name": "Mr. Michael S. Weiss Esq., J.D.", "age": 58, "title": "Chairman, CEO & President", "yearBorn": 1966, "fiscalYear": 2024, "totalPay": 1970938, "exercisedValue": 0, "unexercisedValue": 26229992}, {"maxAge": 1, "name": "Mr. Sean A. Power CPA", "age": 42, "title": "CFO, Corporate Secretary & Treasurer", "yearBorn": 1982, "fiscalYear": 2024, "totalPay": 780600, "exercisedValue": 0, "unexercisedValue": 8840500}, {"maxAge": 1, "name": "Ms. Jenna  Bosco", "title": "Senior Vice President of Corporate Communications", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Adam  Waldman", "title": "Chief Commercialization Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 10, "compensationRisk": 10, "shareHolderRightsRisk": 3, "overallRisk": 10, "governanceEpochDate": 1754006400, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 27.89, "open": 27.5, "dayLow": 26.52, "dayHigh": 27.92, "regularMarketPreviousClose": 27.89, "regularMarketOpen": 27.5, "regularMarketDayLow": 26.52, "regularMarketDayHigh": 27.92, "payoutRatio": 0.0, "beta": 1.948, "trailingPE": 70.289474, "forwardPE": 27.536081, "volume": 4755175, "regularMarketVolume": 4755175, "averageVolume": 1993374, "averageVolume10days": 3600620, "averageDailyVolume10Day": 3600620, "bid": 26.42, "ask": 26.83, "bidSize": 24, "askSize": 24, "marketCap": 4240346112, "fiftyTwoWeekLow": 20.045, "fiftyTwoWeekHigh": 46.48, "priceToSalesTrailing12Months": 9.338551, "fiftyDayAverage": 36.0557, "twoHundredDayAverage": 34.1739, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 3873088000, "profitMargins": 0.13315, "floatShares": 135059143, "sharesOutstanding": 158755008, "sharesShort": 24169314, "sharesShortPriorMonth": 23697171, "sharesShortPreviousMonthDate": 1749772800, "dateShortInterest": 1752537600, "sharesPercentSharesOut": 0.1522, "heldPercentInsiders": 0.09738, "heldPercentInstitutions": 0.63342, "shortRatio": 15.5, "shortPercentOfFloat": 0.1991, "impliedSharesOutstanding": 158755008, "bookValue": 1.634, "priceToBook": 16.34639, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "earningsQuarterlyGrowth": 3.098, "netIncomeToCommon": 60458000, "trailingEps": 0.38, "forwardEps": 0.97, "lastSplitFactor": "100:5625", "lastSplitDate": 1335744000, "enterpriseToRevenue": 8.53, "enterpriseToEbitda": 45.097, "52WeekChange": 0.2934625, "SandP52WeekChange": 0.19554341, "quoteType": "EQUITY", "currentPrice": 26.71, "targetHighPrice": 53.0, "targetLowPrice": 11.0, "targetMeanPrice": 40.5, "targetMedianPrice": 46.0, "recommendationMean": 1.75, "recommendationKey": "buy", "numberOfAnalystOpinions": 6, "totalCash": 276240000, "totalCashPerShare": 1.894, "ebitda": 85884000, "totalDebt": 254583008, "totalRevenue": 454068992, "debtToEquity": 107.288, "revenuePerShare": 3.111, "grossProfits": 394848992, "earningsGrowth": 3.25, "revenueGrowth": 0.921, "grossMargins": 0.86958003, "ebitdaMargins": 0.18913999, "operatingMargins": 0.24685, "financialCurrency": "USD", "symbol": "TGTX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "longName": "TG Therapeutics, Inc.", "regularMarketChangePercent": -4.23091, "regularMarketPrice": 26.71, "corporateActions": [], "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1272893400000, "postMarketChangePercent": -0.187193, "postMarketPrice": 26.66, "postMarketChange": -0.0499992, "regularMarketChange": -1.18, "regularMarketDayRange": "26.52 - 27.92", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 1993374, "fiftyTwoWeekLowChange": 6.664999, "fiftyTwoWeekLowChangePercent": 0.33250183, "fiftyTwoWeekRange": "20.045 - 46.48", "fiftyTwoWeekHighChange": -19.77, "fiftyTwoWeekHighChangePercent": -0.42534426, "fiftyTwoWeekChangePercent": 29.346252, "earningsTimestamp": 1754310600, "earningsTimestampStart": 1762259400, "earningsTimestampEnd": 1762259400, "earningsCallTimestampStart": 1754310600, "earningsCallTimestampEnd": 1754310600, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": 0.38, "epsForward": 0.97, "epsCurrentYear": 0.75597, "priceEpsCurrentYear": 35.33209, "fiftyDayAverageChange": -9.345699, "fiftyDayAverageChangePercent": -0.25920174, "twoHundredDayAverageChange": -7.4639015, "twoHundredDayAverageChangePercent": -0.2184094, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.8 - Buy", "postMarketTime": 1754697572, "regularMarketTime": 1754683200, "exchange": "NCM", "messageBoardId": "finmb_143627354", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "cryptoTradeable": false, "shortName": "TG Therapeutics, Inc.", "displayName": "TG Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-08-09"}]